Uppsala, Sweden – November 30, 2018 – Orexo AB (publ.) today announces that the US Court of Appeals for the Federal Circuit has denied Actavis Elizabeth LLC’s (Actavis) combined petition for panel rehearing and rehearing en banc in the case regarding Orexo’s Zubsolv US patent 8,940,330.
On September 10, 2018, the US Court of Appeals reversed the invalidity decision previously rendered by the District Court of Delaware in November 2016 and found Orexo’s long term Zubsolv US patent 8,940,330 to be valid. The patent expires in 2032. On October 24, 2018, Actavis filed a petition for panel rehearing and rehearing en banc, which has now been denied.
Orexo will host a Capital Markets Day on December 6, in Stockholm, Sweden, to share information about the company strategy following the positive outcome of the patent litigation process against Actavis. The complete program and information about registration is available on the Company´s corporate web site.
For further information, please contact:
|Orexo AB (publ.)|
|Nikolaj Sørensen, President and CEO||Lena Wange, IR and Communications Manager|
|Tel: +46 (0)18 780 88 00||Tel: +46 (0)18 780 88 00|
|E-mail: email@example.com||E-mail: firstname.lastname@example.org|
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.
The information was submitted for publication at 8:00 am CET on November 30, 2018